Accuray Incorporated (ARAY)

US — Healthcare Sector
Peers: SRDX  AXGN  BVS  CUTR  NUVA  FNA  OFIX  SIBN  AVNS  AZYO  APYX  INVO  AORT  ANIK  SGHT  CTSO  NPCE  CLPT  TELA  KIDS 

Automate Your Wheel Strategy on ARAY

With Tiblio's Option Bot, you can configure your own wheel strategy including ARAY - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol ARAY
  • Rev/Share 4.5247
  • Book/Share 0.4822
  • PB 3.2973
  • Debt/Equity 4.3234
  • CurrentRatio 1.6392
  • ROIC 0.0081

 

  • MktCap 163790670.0
  • FreeCF/Share 0.1851
  • PFCF 8.6056
  • PE 242.9298
  • Debt/Assets 0.4426
  • DivYield 0
  • ROE 0.0143

 

  • Rating C+
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 2
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

Why Is Accuray (ARAY) Up 17% Since Last Earnings Report?
ARAY
Published: May 30, 2025 by: Zacks Investment Research
Sentiment: Positive

Accuray (ARAY) reported earnings 30 days ago. What's next for the stock?

Read More
image for news Why Is Accuray (ARAY) Up 17% Since Last Earnings Report?
Accuray to Participate in the Jefferies Global Healthcare Conference 2025
ARAY
Published: May 29, 2025 by: PRNewsWire
Sentiment: Neutral

MADISON, Wis. , May 29, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today its participation in the Jefferies Global Healthcare Conference 2025.

Read More
image for news Accuray to Participate in the Jefferies Global Healthcare Conference 2025
Here's Why You Should Hold Accuray Stock in Your Portfolio for Now
ARAY
Published: May 15, 2025 by: Zacks Investment Research
Sentiment: Positive

ARAY continues to witness strength in its flagship, CyberKnife system, along with robust global performance.

Read More
image for news Here's Why You Should Hold Accuray Stock in Your Portfolio for Now
Accuray Showcases New Long-Term Data¹ on Benefits of 5 Session Radiotherapy Treatment for Men with Prostate Cancer at ESTRO 2025
ARAY
Published: May 07, 2025 by: PRNewsWire
Sentiment: Neutral

More than 40 Clinical Studies Using Accuray Technology Presented at ESTRO 2025; Company Highlights Innovation and Educational Symposia MADISON, Wis. , May 7, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that new data presented at the European Society for Radiotherapy and Oncology (ESTRO) meeting reinforces the benefits of the company's CyberKnife ® System in the treatment of prostate cancer at multiple stages of the cancer journey.

Read More
image for news Accuray Showcases New Long-Term Data¹ on Benefits of 5 Session Radiotherapy Treatment for Men with Prostate Cancer at ESTRO 2025
ARAY Stock Down Despite Q3 Earnings Beat Estimates, Revenues Up Y/Y
ARAY
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Positive

Accuray reports solid fiscal third-quarter results, witnessing growth in Product & Services revenues and reduced operating expenses.

Read More
image for news ARAY Stock Down Despite Q3 Earnings Beat Estimates, Revenues Up Y/Y
Accuray Incorporated (ARAY) Q3 2025 Earnings Call Transcript
ARAY
Published: April 30, 2025 by: Seeking Alpha
Sentiment: Neutral

Accuray Incorporated (NASDAQ:ARAY ) Q3 2025 Earnings Call April 30, 2025 4:30 PM ET Company Participants Jesse Chew - Chief Legal Officer Suzanne Winter - President and Chief Executive Officer Ali Pervaiz - Chief Financial Officer Conference Call Participants Brooks O'Neil - Lake Street Capital Markets Marie Thibault - BTIG Jason Wittes - ROTH Capital Operator Good day and welcome to the Accuray Third Quarter Fiscal 2025 Financial Results Conference Call. [Operator Instructions] Please note this event is being recorded.

Read More
image for news Accuray Incorporated (ARAY) Q3 2025 Earnings Call Transcript
Here's Why You Should Hold Accuray Stock in Your Portfolio for Now
ARAY
Published: March 05, 2025 by: Zacks Investment Research
Sentiment: Positive

ARAY continues to witness strength in its flagship CyberKnife system, along with robust global performance.

Read More
image for news Here's Why You Should Hold Accuray Stock in Your Portfolio for Now

About Accuray Incorporated (ARAY)

  • IPO Date 2007-02-08
  • Website https://www.accuray.com
  • Industry Medical - Specialties
  • CEO Ms. Suzanne Winter M.B.A.
  • Employees 987

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, China, and rest of the Asia Pacific region. It offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. The company also provides the TomoTherapy System, including the Radixact System, which allows for integrated radiation treatment planning, delivery, and data management, enabling clinicians to deliver ultra-precise treatments to approximately 50 patients per day; iDMS data management system, a fully integrated treatment planning and data management systems; and Accuray precision treatment planning system, a treatment planning and data management systems. In addition, it offers post-contract customer support, installation, training, and other professional services. The company primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Madison, Wisconsin.